📰T-cell immunoglobulin and mucin-domain containing-3 (TIM3) have been identified as a potential target for acute myeloid leukemia (AML) treatment. Research shows that TIM3 CAR T-cells can effectively target and eliminate TIM3+ leukemic cells while sparing healthy cells, offering

Recent studies show that pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients exhibit significant natural immunity, challenging the notion that low tumor mutational burden restricts immunogenicity. This finding opens new avenues for targeted, personalized

Join millions who have switched to Grok.

This study on #anticoagulation in patients nearing end of life reveals a decline in vitamin K antagonist control, marked by reduced time in therapeutic range  and increased time above therapeutic range and variance growth rate, suggesting higher bleeding risk. #VKA

🎧Replay. In this episode of the HemaSphere podcast, host Charles de Bock and guest Tim Mocking discuss the role of machine learning in the assessment of measurable residual disease (MRD) in acute myeloid leukemia #AML. They explore the challenges of MRD detection, the potential

The CHIC framework, developed to predict the presence of high-risk clonal hematopoiesis (CH-HRG) from CBC variables and age, represents a significant step towards scalable, practical, and cost-effective screening for #CH-HRG, potentially reducing the need for extensive genetic

This study identifies early relapse (ER) in newly-diagnosed multiple myeloma (#MM) patients, highlighting a 22% ER rate within 18 m & median OS of 19 m for ER cases vs 114 months for non-ER cases. A predictive model for ER18 is proposed to improve survival outcomes.

ADAMTS13's conformational regulation is crucial for its enzymatic function and the pathophysiology of thrombotic thrombocytopenic purpura. Open ADAMTS13 has emerged as a novel biomarker for acute and subclinical iTTP, aiding in the prediction of early relapses during patient

📰This study highlights the effectiveness of nivolumab combined with ICE chemotherapy in patients with #RR cHL. The regimen achieved a 100% OR rate and 86% CR rate, with high survival rates and manageable toxicity. 👉

🚨NEW PODCAST EPISODE🚨. In this second part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology, particularly focusing on #AML. They discuss the challenges and

The recent paper discusses a retrospective study on thrombotic risk in classical Hodgkin lymphoma (#cHL) patients. It introduces the Thro-HL risk model, which combines various factors to predict thrombotic events, showing significant differences in thrombotic event rates among

The monitoring of MRD using multicolor flow cytometry (MFC-MRD) or PCR is the most powerful tool for assessing treatment response in childhood #BCP-ALL. Recent improvements in #MFC-MRD allow higher sensitivity, providing additional clinically valuable information. Read more in

🔬 Dive into the latest research with @Hemasphere_EHA! Our open access articles provide ground-breaking insights into #hematology. Stay ahead in your field and collaborate with peers. Our latest issue in progress can always be found here 👉 #Research.

This Review article discusses advancements in treating newly diagnosed multiple myeloma (NDMM). It highlights the use of carfilzomib-based triplet and quadruplet combinations, including KRd, Isa-KRd, and D-KRd, which show deep and durable responses, even in high-risk #NDMM

The MonumenTAL-1 trial confirms talquetamab's efficacy and safety in treating relapsed/refractory multiple myeloma. Despite high-risk factors, a 65% response rate and 6.4 months median progression-free survival were observed. These findings support use in advanced stages.

🎙️NEW PODCAST EPISODE. In this 2-part episode of the HemaSphere podcast, host Dr Charles de Bock and guests Dr Jörg Büscher and Prof Dr Petya Apostolova the critical role of metabolism in cellular function, particularly in the context of hematology and cancer research. The

RT @EHA_Hematology: Over 300,000 blood cancer patients start their cancer journey every year – but they are all different. 🎯 EHA and @Eu….

VEXAS syndrome, caused by UBA1 mutations, leads to various autoinflammatory symptoms and severe anemia. Chronic inflammation contributes to anemia, and controlling it can help achieve RBC transfusion independence. The study evaluates the response to erythroid-stimulating agents

Not all red blood cells are created equal. 🩸Why have  #Fcells have attracted considerable interest?. Read about in this impactful papar👉

🔥This NLG biomarker-driven study shows that intensive immunochemotherapy combined with early HD-Mtx and HD-AraC as consolidation is feasible and effective in patients with biologically high-risk LBCL. @LeppaSM. 👉